+ND Capital — 2018 Investments
2 investments dated 2018 · listed companies and verified rows first · show all
Serotiny designs cell therapies using custom software and lab techniques that allow it to design and test up to 10,000 therapeutic genes at once, aiming to speed up the discovery of treatments for cancers such as multiple myeloma, prostate cancer and lung cancer.
AI & Machine LearningBiotechHealthtechSan Francisco, US
Justin Farlow(Co-founder)inColin Farlow(Co-founder)Eric Moessinger(Director)in
Co-investors8VC
BiotechWatertown, US
Robert S. Langer, Sc.D.(Director)Armon Sharei, Ph.D.(Executive Officer, Director)Armon Sharei(Executive Officer, Director)Amy W. Schulman(Executive Officer, Director)Kris Elverum(Executive Officer)Howard Bernstein(Executive Officer)
Co-investorsAlumni VenturesGV (Google Ventures)Illumina VenturesInvusJDRF T1D FundQuark Venture Inc.+2 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.







